Direkt zum Inhalt
Merck
  • Exploration of (3-benzyl-5-hydroxyphenyl)carbamates as new antibacterial agents against Gram-positive bacteria.

Exploration of (3-benzyl-5-hydroxyphenyl)carbamates as new antibacterial agents against Gram-positive bacteria.

Archiv der Pharmazie (2020-01-03)
Hua-Ju Liang, Ya-Juan Cheng, Lu-Xia Wang, Bao-Qin Huang, Niu-Niu Zhang, Jie Liang, Ming Yan
ZUSAMMENFASSUNG

A series of (3-benzyl-5-hydroxyphenyl)carbamates were evaluated as new antibacterial agents. Several compounds showed potent inhibitory activity against sensitive and drug-resistant Gram-positive bacteria. The compounds are ineffective against all tested Gram-negative bacteria. The structure of the ester group exerted a profound effect on antibacterial activity. 4,4-Dimethylcyclohexanyl carbamate 6h exhibited the most potent inhibitory activity against the standard and clinically isolated Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecalis (minimum inhibitory concentration = 4-8 µg/ml) strains. The preliminary experimental evidence indicated that these carbamates target the bacterial cell wall and share a similar mechanism of action with vancomycin.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Polymyxin B nonapeptide hydrochloride, cationic cyclic peptide